• Novobiocin Workflows for Resistance Research

  2026-09-18

  Build clearer susceptibility, membrane-dynamics, antiparasitic, and antiviral assays with Novobiocin, an aminocoumarin antibiotic that links bacterial DNA replication to broader cellular phenotypes. This guide emphasizes concentration design, resistant-staphylococci comparisons, formulation control, and practical troubleshooting.

• ATRNL1 and Cell-Type Signals in Atrial Fibrillation

  2026-09-18

  This study uses large-scale single-nucleus RNA sequencing to define cell-type-specific transcriptional changes in human left atrial tissue from patients with atrial fibrillation. Its identification of ATRNL1 dysregulation in cardiomyocytes, followed by functional perturbation in human stem cell-derived cardiomyocytes, links this gene to cellular stress responses and cardiac electrical activity.

• SFRP1, Neutrophils, and Wnt Signaling in Oral Fibrosis

  2026-09-17

  A 2024 study links reduced SFRP1 with neutrophil infiltration, fibrosis, and increased Wnt/β-catenin pathway activity in an arecoline-induced oral submucous fibrosis model. SFRP1 overexpression reduced these pathological features, whereas pathway activation weakened its protective effects, supporting a mechanistic connection between inflammatory recruitment and fibrotic signaling.

• ATS-9R for Targeted Gene Silencing in Adipocytes

  2026-09-17

  ATS-9R combines Prohibitin recognition with nona-arginine-mediated nucleic acid condensation for targeted delivery to white adipose tissue. This workflow supports gene silencing in adipocytes and adipose tissue macrophages while providing practical controls for formulation, tissue distribution, and metabolic readouts.

• Ribonuclease R Workflow for Circular RNA Studies

  2026-09-16

  Learn how topology-selective RNA digestion can enrich circular transcripts for validation, sequencing, and mechanistic studies. This workflow pairs Ribonuclease R with no-enzyme controls and orthogonal assays so RNase resistance is interpreted as evidence—not proof—of circularity.

• ML216: From BLM Inhibition to Assay Design

  2026-09-16

  ML216, a BLM helicase inhibitor, can reveal how DNA repair dependencies shape cellular phenotypes. This article connects biochemical target engagement with BLM-proficient controls, orthogonal readouts, and the interpretive limits of translating RecQ-helicase findings into cancer models.

• Biotin-XX Tyramide Reagent: Practical Guide

  2026-09-15

  Learn how Biotin-XX Tyramide Reagent, SKU A8012, can improve localized signal amplification and cell-surface protein labeling in demanding assay workflows. This scenario-based guide covers membrane selectivity, compatibility, optimization, interpretation, and practical supplier-selection criteria.

• Separating Growth Arrest from Cell Death in Cancer Assays

  2026-09-15

  Hannah R. Schwartz’s dissertation identifies a critical interpretive problem in anticancer drug testing: relative viability and fractional viability are often treated as interchangeable even though they measure different biological outcomes. Its framework encourages researchers to separate proliferation arrest from cell killing, improving time-course interpretation, assay selection, and translation across cancer models.

• Canagliflozin and Proximal Tubule Mitochondria

  2026-09-14

  Explore how Canagliflozin links SGLT2 inhibition with proximal-tubule mitochondrial remodeling. This article translates recent hypertensive-diabetic mouse findings into practical decisions for renal, metabolic, and bioenergetic research.

• NMDA (N-Methyl-D-aspartic acid) Research Guide

  2026-09-14

  NMDA (N-Methyl-D-aspartic acid) is a direct NMDA receptor agonist used to model receptor-driven excitotoxic injury. This guide connects its chemical handling, calcium influx measurement, oxidative stress readouts, and use in NMDA-induced glaucoma models.

• BCA Protein Assay Kit: Reliable Cell Assays

  2026-09-13

  Learn how the BCA Protein Assay Kit, SKU K4101, supports reproducible protein concentration measurement in cell viability, proliferation, and cytotoxicity workflows. This scenario-based guide connects assay principles, protocol decisions, interpretation, and vendor selection to practical laboratory needs.

• Doxycycline Hyclate in MMP Research

  2026-09-12

  Doxycycline hyclate provides a practical way to connect MMP activity with blood–brain barrier failure, neuronal injury, and vascular inflammation. This workflow-centered guide explains how to prepare, apply, validate, and troubleshoot the compound across neurovascular and selected infectious-disease models.

• PDHA1 Succinylation and α-KGA in Cholangiocarcinoma

  2026-09-11

  A 2025 Nature Communications study identifies PDHA1 lysine 83 succinylation as a metabolic switch that increases alpha-ketoglutaric acid in the cholangiocarcinoma microenvironment. The resulting OXGR1–MAPK signal suppresses macrophage MHC-II antigen presentation, while pharmacological pathway inhibition improves gemcitabine–cisplatin activity in preclinical models.

• PTSD Heart–Brain Dysregulation in Mice

  2026-09-11

  A 2026 European Journal of Pharmacology study identifies a vagus-mediated heart-to-insula pathway linking sympathetic cardiac overactivation with PTSD-like behavior in mice. Its combination of isoproterenol challenge, vagotomy, electrophysiology, and propranolol treatment offers a useful framework for testing causal heart–brain interactions.

• Doxycycline hyclate for BBB Research

  2026-09-10

  Doxycycline hyclate is a practical matrix metalloproteinases inhibitor for connecting MMP-2/MMP-9 activity with blood–brain barrier failure, neuronal apoptosis, and behavioral change. This guide translates a mouse arsenic-exposure study into reproducible preparation, assay-selection, troubleshooting, and cross-domain research workflows.

3604 records 1/241 page Next 12345 下5页 Last page